Navigation Links
Poniard Pharmaceuticals Awarded $244,479 Grant Under Qualifying Therapeutic Discovery Project Program
Date:11/4/2010

SOUTH SAN FRANCISCO, Calif., Nov. 4, 2010 /PRNewswire/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that it has been awarded $244,479 in grant funding as part of the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program established under Section 48D of the Internal Revenue Code. Poniard plans to use the grant to advance the development of its lead product candidate, picoplatin, in the treatment of cancer.

"This grant serves as recognition of picoplatin's potential as a new therapy to treat areas of unmet medical needs for solid tumors,"  said Ronald A. Martell, chief executive officer of Poniard Pharmaceuticals. "We plan to use the proceeds from the grant to support our ongoing clinical and regulatory objectives, which are aimed at advancing picoplatin into pivotal testing in one of several solid-tumor indications in which it has demonstrated promising results."

The QTDP was created by Congress in March 2010 as part of the Patient Protection and Affordable Care Act. Eligibility for the grant requires that a project have the potential to develop new treatments that address unmet medical needs or chronic and acute diseases, reduce long-term health care costs or represent a significant advance in finding a cure for cancer.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products. For additional information please visit http://www.poniard.com.

Forward-Looking Statements

This release contains forward-looking statements describing, among other things, the Company's projected financial position and future operations, the adequacy of its cash resources, the Company's pla
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Haemonetics Corporation (NYSE: HAE ) announced today that ... will present at The Deutsche Bank 38 th Annual ... on May 29, 2013 at 1:30pm Eastern time.  ... public may access Mr. Lindop,s presentation live via webcast at: ... Haemonetics (NYSE: HAE ) is a global healthcare ...
(Date:5/23/2013)... 23, 2013  MGC Diagnostics Corporation (NASDAQ: ... company, today scheduled a conference call to discuss its ... 2013, ended April 30, 2013. The call will be ... The Company will report financial results for the second ... on Thursday, May 30, 2013. (Logo: ...
(Date:5/23/2013)... Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly ... property developed and owned by Hadassah University Hospital, ... center, today announced that its portfolio company, Cell ... Israeli Ministry of Industry and Commerce, Office of ... and advance clinical trials. Cell Cure,s development budget ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
(Date:5/25/2013)... Plains, NJ (PRWEB) May 25, 2013 ... iPhone. The universal app version of Word Hunt ... app versions of Concentration, Edge Match, Flash 2, Sudoku and ... , The brain games’ gameplay and revolutionary lifetime brain fitness ... 4 inch displays. , “100 years of brain fitness measurement ...
(Date:5/25/2013)... Los Angeles, CA (PRWEB) May 25, 2013 ... will grow at an average annual rate of 28.7% ... growth of 17.9% in 2013. From 2002 and 2008, no ... analyst Kevin Culbert, causing relatively modest growth during that period. ... (FDA) has approved six new products. This factor contributed to ...
(Date:5/25/2013)... Texas (PRWEB) May 25, 2013 ... stressful than finals week. Increasingly, they are turning ... stay awake and study. For more on this, ... a drug treatment facility, warns that students who ... finals” are at risk for developing a physical ...
(Date:5/25/2013)... 2013 Ayurveda is the traditional ... or wisdom of life". While a medical science, its scope ... of consciousness. Its fundamental philosophy is that disease is the ... It believes that in order to re-establish optimal health, we ... then adopt a life style which brings us back into ...
(Date:5/25/2013)... May 25, 2013 The current residents of ... parents, and the B2B staff all came together Saturday, May ... an array of Indian Cuisine, the residents got up to ... helping them on their road to recovery, and giving them ... and Alcohol center in 2010 after realizing the need for ...
Breaking Medicine News(10 mins):Health News:Acuity Games Apps Come to the iPhone 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes 2Health News:Back2Basics Drug and Alcohol Rehabilitation Center Celebrates Their 3rd Anniversary 2
... more sensitive to early signs of Alzheimer,s dementia than ... School of Medicine in St. Louis. Doctors often ... testing them with a variety of cognitive tasks, such ... of objects. Washington University researchers developed a different approach. ...
... By Randy Dotinga HealthDay Reporter , MONDAY, Sept. ... the devastation suffered by men when their wives or girlfriends ... were almost 40 percent more likely than other men to ... risk of hospitalization among the men was very small, and ...
... Inc. is presenting new data in five posters and ... the company,s radioprotectant Ex-RAD at the 56th Annual Meeting ... Maui, Hawaii. In vivo studies show that Ex-RAD, ... versus placebo-treated groups in mice exposed to lethal whole ...
... best practice and endorsement of evidence-based medicine, the American ... and released a clinical practice guideline, which found a ... a way to treat fractures in the spine. ... to ensure that patients receive high quality care. ...
... and military efforts continuing in Afghanistan, UCLA has helped ... forces medical personnel in critical combat casualty care. The ... program,s developers say, but civilian care as well. ... the field during Operation Iraqi Freedom and Operation Enduring ...
... first studies to focus exclusively on the outcomes ... http://www.mayoclinic.org/prostate-cancer/ ) researchers have found that surgery provides ... and Fox Chase Cancer Center ( http://www.fccc.edu/ ) ... aggressive forms of prostate cancer who had radical ...
Cached Medicine News:Health News:Friends, family detect early Alzheimer's signs better than traditional tests 2Health News:Friends, family detect early Alzheimer's signs better than traditional tests 3Health News:Male Partners of Breast Cancer Patients May Suffer Depression 2Health News:Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting 2Health News:Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting 3Health News:New guideline finds no evidence for a popular back procedure 2Health News:New guideline finds no evidence for a popular back procedure 3Health News:UCLA develops combat casualty care educational program for US armed forces 2Health News:UCLA develops combat casualty care educational program for US armed forces 3Health News:Surgery found effective for patients with aggressive prostate cancer 2
... for a complete line of diagnostic coronary ... with the quality, reliability and precise performance ... in catheter technology. All of our coronary ... to help minimize the frustration and excess ...
The Polaris-DX steerable diagnostic catheter is designed for comfort and ergonomic handling during mapping procedures....
... of the PARAHISIAN catheter, combines an octapolar ... permits the use of only one catheter ... His bundle electrograms. The "two catheters in ... a single venipuncture. The disadvantages of using ...
... HIS diagnostic catheters provide the ... curve that allows for placement ... bundle. In addition, the soft ... the risk of perforation while ...
Medicine Products: